Serum levels of GH, IGF-I, LH and ovarian steroids in cyclic and RU486-treated rats.
Rats lacking progesterone action due to RU486 treatment have been reported to show numerous endocrine and morphological similarities with respect to human polycystic ovary syndrome (PCO). Nevertheless, abnormalities on insulin or insulin-like growth factor I (IGF-I) production, a frequent finding in the polycystic disease, have not been studied in such rats yet. The aim of these experiments was to evaluate the serum concentrations of IGF-I in rats treated with 4 mg of the antiprogestagen RU486 over 4 or 8 consecutive days starting on estrus (day 1) and decapitated on the morning of day 5 and 9. Serum levels of growth hormone (GH), luteinizing hormone (LH), testosterone (T) and 17 beta estradiol (E2) were determined and correlated with those of IGF-I. Controls were rats injected with oil and killed in the morning of metestrus, diestrus, proestrus and estrus. Rats treated with RU486 had increased serum concentrations of IGF-I, LH, T and E2 with respect to control rats on estrus, while no differences were found in the serum concentrations of GH. Parallel estrous cycle related changes were observed in the serum concentrations of IGF-I, T and E2 with the highest values at proestrus. However, changes on serum concentrations of GH were not associated with those of IGF-I in control rats through the estrous cycle. The present results are consistent with the idea that beside on GH, serum concentrations of IGF-I in the rat depend also on LH or LH-dependent ovarian steroid production. Moreover, the results indicate that IGF-I production increased in RU486-treated rats, which may have a role in the ovarian abnormalities induced by RU486 treatment in the rat.
Ruiz
A
A
Department of Physiology, Faculty of Medicine, University of Córdoba, Spain.
Tébar
M
M
Pérez-Romero
A
A
Rol de Lama
M A
MA
Sánchez-Criado
J E
JE
D000818:Animals; D004031:Diestrus / Q000502:physiology; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000502:physiology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D013006:Growth Hormone / Q000097:blood*; D006727:Hormone Antagonists / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood*; D015735:Mifepristone / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome; D011374:Progesterone / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D013739:Testosterone / Q000097:blood
D012739:Gonadal Steroid Hormones; D006727:Hormone Antagonists; D015735:Mifepristone; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D013006:Growth Hormone